Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
National Institutes of Health
Inicia sesión y completa tu Funding Passport para ver si calificas — un veredicto transparente basado en reglas, no una caja negra.
Iniciar sesiónSobre esta oportunidad
The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.
Documentos requeridos
La fuente oficial no indica documentos específicos aquí — confirme los requisitos antes de postular.
Fuente y trazabilidad de verificación
- Fuente oficial
- U.S. Federal Government (Grants.gov) ↗
- Primera obtención
- 20 de noviembre de 2026
- Última verificación
- 20 de noviembre de 2026
- Huella del contenido
9eec49a7a957ec44…